An independent data monitoring committee completed a planned review of interim results and concluded that the data are unlikely to provide evidence of significant effect. No safety concerns were reported.
The study was being conducted by the Parkinson Study Group, a non-profit, cooperative group of Parkinson’s disease experts from medical centers in the US and Canada, who are dedicated to improving treatment for persons affected by Parkinson’s disease.
“While we are disappointed with results of the trial, our collaboration with Lundbeck will continue as a valuable part of our ongoing research program in neurodegenerative disorders,” said Dr Jeffry Vaught, senior vice president and president of R&D at Cephalon. “We will continue to actively evaluate compounds for further clinical development with Lundbeck.”
Despite the bad news, both companies’ stock has climbed following the announcement, with Lundbeck seeing the greatest increase, up 1.2% on the Copenhagen Stock Exchange.